

## DECLARATION OF CONFORMITY

**Corporate Office:** Quidel Corporation  
10165 McKellar Court  
San Diego, California 92121  
USA

**Manufacturer:** Quidel Corporation  
Northern California Operations  
2981 Copper Road  
Santa Clara, California 95051  
USA


**Product Name:** MicroVue™ DPD EIA Kit

**Description:** MicroVue DPD is a urinary assay that provides a quantitative measure of the excretion of deoxypyridinoline (DPD) crosslinks as an indicator of bone resorption. Elevated levels of urinary DPD indicate elevated bone resorption in individuals. Measurement of DPD is intended for use as an aid in monitoring bone resorption changes in postmenopausal women receiving hormonal or bisphosphonate antiresorptive therapies and in individuals diagnosed with osteoporosis.

**Classification:** **Article 9, paragraph 1 of EC Council Directive 98/79/EC on *In Vitro* Diagnostic Medical Devices**

**Estimated Start of CE-Marking:** **December 19, 2003**

Quidel Corporation, being the manufacturer within the European Economic Area, hereby declares that the products covered by the declaration conform with the Essential Requirements of EC Directive 98/79/EC. Supporting documentation is retained under the premises of the manufacturer.

Signed 

Date 11/9/09